Over recent months, significant Parkinson’s breakthroughs have emerged, offering renewed hope to millions of people living with the condition worldwide.
Recent scientific strides could transform the landscape of Parkinson’s research, promising fresh insights, refined diagnostics and innovative therapies.
Here NR Times presents a compilation of these groundbreaking discoveries, each contributing to the understanding, diagnosis and treatment of Parkinson’s disease.
P2B001: a promising breakthrough in Parkinson’s treatment set to gain regulatory approval
P2B001, an innovative combination therapy developed by Pharma Two B, is on the verge of seeking regulatory approval in the US this year.
The medication manages Parkinson’s disease symptoms by combining pramipexole and rasagiline, outperforming their individual use regardless of patient age or disease severity.
This was demonstrated in a Phase 3 trial completed earlier this year. This oral, low-dose therapy offers a prolonged release of dopamine activity in the brain, enhancing dopamine levels through rasagiline.
It has shown promise in optimising patient care while challenging conventional treatment paradigms.
These findings underscore the drug’s potential to revolutionise Parkinson’s management. Unlike its counterparts, P2B001 exhibits fewer side effects related to sleepiness.
NLX-112: New Parkinson’s drug by 2030?
A recent clinical trial, partially funded by Parkinson’s Virtual Biotech, has unveiled encouraging results regarding NLX-112, a potential game-changer for both motor symptoms and dyskinesia.
While initially focused on addressing the latter, this trial unexpectedly demonstrated positive impacts on other Parkinson’s motor symptoms, including slowness, stiffness and tremor, symptoms that can significantly affect daily life.
Typically, common Parkinson’s drugs convert into dopamine, but NLX-112 takes a fresh approach by targeting serotonin-carrying brain cells, essential for movement control.
In the trial, 22 participants experienced reduced dyskinesia, akin to current treatments, and improved motor symptoms similar to dopamine agonists. Results improved with higher doses, suggesting more promise for the drug in later phases.
The drug, if successful in subsequent trials, could be used as a new Parkinson’s treatment by 2030.
Dopamine biomarker breakthrough
Lund University scientists, led by Oskar Hansson, have unveiled a potent biomarker for identifying all types of Parkinson’s-related diseases: the enzyme DOPA decarboxylase (DCC).
The study, published in Nature Aging, reveals DCC’s elevated levels in individuals with Parkinson’s and other dopamine-deficiency-related diseases, even years before symptoms manifest.
Importantly, DCC can be detected in blood samples, simplifying diagnosis, especially for Parkinson’s disease.
Traditional methods, such as PET camera examinations are complex and come with financial barriers. DCC, therefore could be a potential game-changer.
“We found that if a patient has a disorder in the dopamine system, the levels of the biomarker DDC increase, regardless of where they are in the course of the disease.
An important discovery is that this biomarker can be measured in blood, where it is significantly increased, especially in Parkinson’s disease,” said study leader, Oskar Hansson.
A significant discovery funded by the Michael J. Fox Foundation
A new scientific breakthrough has the potential to transform the diagnosis and treatment of Parkinson’s disease. It revolves around the identification of alpha-synuclein, a misfolded protein, as a dependable marker of the disease.
Currently, detecting alpha-synuclein requires a spinal tap, an invasive procedure. However, scientists are optimistic that future methods could include blood tests, skin biopsies or even nasal swabs.
The results, published in The Lancet Neurology, stem from a comprehensive 1,123-person study that has consumed hundreds of millions of dollars since 2010.
This advancement holds immense promise for early diagnosis and expediting treatment research, although it will take more time and research before patients can be screened through this method.
|
Potential in mRNA technology
Professor Vincent Harley at the Hudson Institute of Medical Research is investigating the use of mRNA technology to target cell death processes linked to Parkinson’s disease.
With a grant of $100,000 from the mRNA Victoria Research Acceleration Fund, he aims to develop a disease-modifying RNA/DNA hybrid molecule that can slow or even halt the neurodegeneration characteristic of Parkinson’s.
Successful trials in rats have laid the groundworks for developing a human version of this promising treatment, offering hope for Parkinson’s patients and their families.
Identifying new enzymes
UConn Health researchers have uncovered a groundbreaking mechanism for potentially treating Parkinson’s Disease. They identified an enzyme called ATIC as a regulator of the LRRK2 gene, which is associated with the disease.
Unlike traditional approaches that target the protein level, the ATIC enzyme works at the mRNA level, controlling the expression of LRRK2.
This discovery opens up new possibilities for pharmaceutical treatments. A drug called AICAr, which mimics ATIC activity, has shown promise in reducing LRRK2 levels in preclinical trials. Xiong’s team is now working on modifying AICAr to penetrate the blood-brain barrier for future Parkinson’s treatments.
Steps forward in stem cell therapy
Bayer subsidiary BlueRock has made progress in treating Parkinson’s disease with an experimental stem cell therapy.
In a Phase I trial involving 12 participants, the therapy showed excellent tolerance and successful growth of transplanted cells in the patients’ brains. Encouraged by these results, BlueRock is advancing to the second phase of testing, with patient enrollment expected in early 2024.
The innovative approach involves transforming pluripotent human embryonic stem cells into dopamine-producing nerve cells, which, when implanted in Parkinson’s patients’ brains, aim to restore neural networks and dopamine production.
This breakthrough brings hope to the over 10 million people worldwide affected by Parkinson’s disease.
Steps forward in AI-enabled diagnostics
A collaboration between the Francis Crick Institute, UCL Queen Square Institute of Neurology and tech firm Faculty AI has developed an AI tool that may improve diagnostics and support more precise treatments.
Their work, featured in Nature Machine Intelligence, demonstrates that machine learning can effectively predict Parkinson’s disease subtypes using images of patient-derived stem cells.
Remarkably, computer models achieved a 95 per cent accuracy in classifying four distinct subtypes, offering a potential pathway to personalised medicine and targeted drug development.
Until now, nonspecific diagnoses hindered access to tailored treatments. The researchers generated stem cells representing four Parkinson’s subtypes and employed advanced imaging to label critical cell components.
Utilising AI, they trained a programme to identify each subtype, primarily focusing on mitochondria and lysosomes, revealing their pivotal role in Parkinson’s development.
